{'fraction_non_alphanumeric': 0.018363939899833055, 'fraction_numerical': 0.011686143572621035, 'mean_word_length': 5.377659574468085, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Differential expression of protein phosphatase 2A activator in cancers of the breast.

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding protein phosphatase 2A activator, PPP2R4, also known as PTPA (protein phosphatase 2 phosphatase activator) when comparing primary tumors of the breast to the tissue of origin, the normal breast. PPP2R4 mRNA was present at significantly higher quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of PPP2R4 in primary tumors of the breast was correlated with recurrence-free survival in patients with basal and luminal B type cancers, but in a contrary manner, demonstrating a complex relationship between correlation of primary tumor expression with recurrence-free survival based on molecular subtype. PPP2R4 may be of relevance to initiation, maintenance or progression of cancers of the female breast.